<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270984</url>
  </required_header>
  <id_info>
    <org_study_id>131HPS10D</org_study_id>
    <nct_id>NCT01270984</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects</brief_title>
  <acronym>Imatinib</acronym>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerance by comparing pharmacokinetic
      characteristics between the Luckyvec 400mg tablet(x 1T) and Glivec 100mg(x 4T) when
      administered a single-dose to healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers are administrated single-dose over the period I and II (Crossover) of
      Luckyvec 400mg tablet(x 1T) and Glivec 100mg(x 4T)as of Imatinib 400mg.

      Every time before and after each medication, PK parameters and safety of Luckyvec 400mg
      tablet and Glivec 100mg is performed using a blood sample and conducting some
      tests(Laboratory test, V/S, Physical Examination, etc) respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of Luckyvec 400mg tablet and Glivec 100mg tablet in healthy subjects</measure>
    <time_frame>0-72hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of Luckyvec 400mg tablet and Glivec 100mg tablet from vital signs, physical exam, ECG, laboratory test, adverse event and so on.</measure>
    <time_frame>0-72hr</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Luckyvec 400mg film coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg/tablet, PO, 1 tablet once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glivec 100mg film coated tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg/tablet, PO, 4 tablets once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luckyvec 400mg film coated tablet</intervention_name>
    <description>•400mg/tablet, PO, 1 tablet once daily for Period I &amp; II D1(crossover)</description>
    <arm_group_label>Luckyvec 400mg film coated tablet</arm_group_label>
    <other_name>Luckyvec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec 100mg film coated tablet</intervention_name>
    <description>•100mg/tablet, PO, 4 tablets once daily for Period I &amp; II D1(crossover)</description>
    <arm_group_label>Glivec 100mg film coated tablet</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 aged and 45 aged in healthy males

          -  BMI: 18~29.9 kg/m2, (BMI = (체중 [kg])/(height [m])2)

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Clinically significant cardiovascular system, pulmonary system, liver system, renal
             system, blood system, gastrointestinal system, immune system, skin system, nervous
             system or mental disease(Past history or present)

          -  Subject with symptoms of acute disease within 28 days of starting administration of
             investigational drug

          -  Subject with known for history which affect on the ADME of drug

          -  Clinically significant active chronic disease

          -  Inadequate result of laboratory test

               -  AST/ALT &gt; 1.5 x UNL

               -  Total bilirubin &gt; 1.5 x UNL

          -  Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test

          -  Taking ETC(ethical the counter)medicine within 14 days

          -  Taking OTC(Over the counter)medicine including oriental medicine within 7 days

          -  Clinically significant allergic disease(Except for mild allergic rhinitis and
             dermatits seems to be not need for medication)

          -  Subject with known for hypersensitivity reaction to imatinib analog

          -  Not able to taking the institutional standard meal

          -  Previously make whole blood donation within 60 days or component blood donation within
             20 days

          -  Previously have blood transfusion within 30 days

          -  Previously participated in other trial within 30 days

          -  Continued to be taking caffeine (caffeine &gt; 5 cup/day), drinking(alcohol &gt; 30 g/day)
             and severe heavy smoker (cigarette &gt; 1/2 pack per day)

          -  An impossible one who participates in clinical trial by investigator's decision
             including for reason of laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>jypark21@korea.ac.kr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

